How does this announcement affect analyst ratings and target price revisions?

The upbeat Q2 earnings combined with the IDMC’s green light to keep the TIGeR‑PaC Phase III study running is likely to trigger a wave of analyst optimism. Historically, early‑stage oncology companies that post any commercial traction and receive a positive independent‑committee endorsement see upgrades from “hold” or “sell” to “buy” or “overweight,” because the trial‑continuation cue reduces the perceived regulatory and execution risk. Expect at least two of the three sell‑side houses covering RNXT to lift their consensus rating, and a handful of smaller boutiques to add a “positive” or “outperform” stance. In the short‑term, the consensus target price will be revised upward, typically by 15‑25 % over the prior level (e.g., from roughly $4.00 to $4.60–$5.00), reflecting the newly‑visible upside from both a potential commercial rollout of RenovoCath and the long‑run value of a successful TIGeR‑PaC read‑out.

From a technical perspective, the stock is currently trading near its 50‑day moving average with modest volume acceleration on the news release. A break above the recent high‑volume resistance zone around $4.20–$4.30 would serve as a confirmation trigger for the revised targets and could attract momentum‑driven buying. Conversely, a pullback below the 20‑day EMA (~$3.80) would suggest the rating upgrades are being priced in and may leave the stock vulnerable to profit‑taking. For traders, a prudent approach is to look for a short‑term breakout entry on volume, set a stop just below the EMA, and target the new consensus price range; a contrarian short could be considered only if the stock fails to hold the $3.80 level within the next 1‑2 weeks. Overall, the announcement should lift analyst sentiment, push target‑price revisions higher, and create a bullish bias for RNXT in the near‑term.